BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 01, 2007
 |  BioCentury  |  Tools & Techniques

Demarcating Alzheimer's

While doctors still rely largely on family history and neuropsychological testing to identify patients with Alzheimer's disease, a new wave of methods are being developed with the potential to diagnose the disease cheaper, faster and - most importantly - earlier.

Beta amyloid, in particular, has received attention as a possible surrogate marker because of its deposition into the insoluble plaques that are a hallmark of AD.

Last month, two groups announced milestones in the development of imaging technologies based on beta amyloid: GE Healthcare (Chalfont St. Giles, U.K.) and its academic partners started a human trial of a radiolabeled imaging agent, and Neuroptix Corp. (Acton, Mass.) signed a deal with Merck & Co. Inc. (MRK, Whitehouse Station, N.J.) to explore the diagnostic utility of measuring beta amyloid in the eye.

Meanwhile, a third group published a study describing an imaging technology that relies on another hallmark of AD, the neurofibrillary tangles that are believed to be caused by tau protein aggregation.

Read the full 815 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >